Designed To Provide Cataract Patients High-Quality Near And Distance
Vision In A Range Of Light Conditions
Advanced Medical Optics, Inc. (AMO) (NYSE:EYE), the global leader in
advanced refractive technologies for eye care professionals and
patients, today announced U.S. Food and Drug Administration (FDA)
approval of the TECNIS® Multifocal intraocular lens (IOL) for
cataract patients.
The TECNIS® Multifocal IOL’s unique design gives patients superior near
vision and reading speed compared to other presbyopia-correcting IOLs,
as well as exceptionally high spectacle independence, with nearly 9 out
of 10 patients reporting that they never wear glasses after surgery.
Other features/benefits include:
-
high-quality vision for near, far and intermediate distances, day or
night;
-
first and only pupil-independent, non-apodized fully diffractive
aspheric lens designed to correct the two highest order aberrations –
spherical and chromatic – to give patients back their youthful vision;
-
95 percent patient satisfaction – the highest of any
presbyopia-correcting IOL.
“The TECNIS® Multifocal IOL delivers a predictable and consistent full
range of vision,” said Ralph Chu, M.D., founder and director of the Chu
Vision Institute in Bloomington, Minn. “The U.S. clinical study shows
that more than 94 percent of patients function comfortably without
glasses for all distances, including intermediate. More importantly, my
own patients are highly satisfied with the results.”
“The full diffractive surface of the TECNIS® Multifocal IOL
provides high-quality vision largely independent of pupil size and
reduces chromatic aberration for better image quality,” said Manfred
Tetz, M.D., professor of ophthalmology and director of
Eye-Center-Spreebogen, Berlin, Germany. “I have been implanting the
TECNIS® Multifocal IOL since 2003 because of the high-quality
visual results that I can provide for my patients, who report being
extremely satisfied with their vision.”
“The introduction of the TECNIS® Multifocal IOL in the U.S.
rounds out AMO’s portfolio of market-leading, refractive technologies,”
said AMO Chairman and CEO Jim Mazzo. “Following years of success in
Europe, U.S.
